ライフサイエンスコーパス: therapy

1 tely facilitate near-real-time diagnosis and therapy.

2 eraction could be efficacious in anaphylaxis therapy.

3 tential resistance mechanisms to AR-targeted therapy.

4 tations infrequently emerged after high-dose therapy.

5 ad changes despite maximal tolerated medical therapy.

6 s to monitoring of antiarrhythmic drug (AAD) therapy.

7 treating cancer patients with adoptive cell therapy.

8 e nodes alone or stereotactic body radiation therapy.

9 on, and also pose major obstacles for cancer therapy.

10 relapsed prostate cancer after primary local therapy.

11 s or extending the duration of HER2-targeted therapy.

12 ent early diagnosis and initiation of proper therapy.

13 hlighting the utility of sequential ROS1 TKI therapy.

14 to improve the efficacy of DSF-based cancer therapy.

15 nsity cholesterol >=100 mg/dl despite statin therapy.

16 rgize with immunotherapy, especially anti-PD therapy.

17 rior to starting a standard-of-care approved therapy.

18 slipidemia taking maximally-tolerated statin therapy.

19 d either prophylactic entecavir or tenofovir therapy.

20 d subsequently harnessed for new concepts in therapy.

21 tumors, and sensitized LN-229 tumors to TMZ therapy.

22 s with HS naive to or having failed anti-TNF therapy.

23 or at the commencement of BRAF/MEK inhibitor therapy.

24 years represents a paradigm shift in cancer therapy.

25 delivery vehicle to carry PMI for anticancer therapy.

26 developing other technologies, such as phage therapy.

27 (TB-IRIS) when they commence antiretroviral therapy.

28 remarkable NIR-II image-guided photothermal therapy.

29 ated adverse effects necessitating change in therapy.

30 cutaneous drug reaction related to entecavir therapy.

31 R status, and HER2 status, and (neo)adjuvant therapy.

32 ing bioabsorbable barriers for root coverage therapy.

33 Additionally, 4 patients were on hormone therapy.

34 strated synergy when combined with anti-PD-1 therapy.

35 compared with traditional dual antiplatelet therapy.

36 ssment for the continued need for antifungal therapy.

37 eters early in direct-acting antiviral (DAA) therapy.

38 cancer have reported low responses to these therapies.

39 ancies treated with chronically administered therapies.

40 vents, which may guide the evaluation of new therapies.

41 cal cytoreductive and/or metastasis-directed therapies.

42 ted with differential response to anticancer therapies.

43 ally difficult to target with small molecule therapies.

44 universal SARS-like coronavirus vaccines and therapies.

45 well as the discovery and development of new therapies.

46 esents a promising target for antimetastatic therapies.

47 pathways simultaneously as effective cancer therapies.

48 eserve cognitive function than single-target therapies.

49 that are uniquely amenable to HER2 blocking therapies.

50 s and rational combination of PVs with other therapies.

51 tentially paving the way to future etiologic therapies.

52 modifications are targets of current cancer therapies.

53 prognosis beyond foundational neurohormonal therapies.

54 ially facilitating the identification of new therapies.

55 ng of cancer growth dynamics and response to therapies.

56 may be a target for periodontal regenerative therapies.

57 for uncovering novel disease mechanisms and therapies.

58 e several advantages over fetal cell-derived therapies.

59 to clinical testing using available targeted therapies.

60 e that is suboptimally responsive to current therapies.

61 disease pathogenesis and ultimately targeted therapies.

62 r pathways could contribute to effective NPC therapies.

63 mit systemic exposure of potent intratumoral therapies.

64 of arrhythmia mechanisms, diagnosis, and new therapies.

65 educe the use of more invasive and expensive therapies.

66 nvestigation given the inadequacy of present therapies(2).

67 rn was observed for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.

68 cutive patients with nAMD received anti-VEGF therapy according to a T&E (n = 163) or PRN (n = 101) re

69 n phase 2, patients treated with combination therapy achieved an overall response rate of 31% (14 of

70 rgeted as part of treatment in adoptive cell therapy (ACT) because of its protumor effects and its ro

71 , asthma progression, asthma occurrence, and therapy adherence.

72 radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of loca

73 the need for postoperative renal replacement therapy after adjustments for confounders.

74 e system for the advent of disease-modifying therapies against AD is imperative.

75 ry, which will further enhance current tumor therapies against various malignant solid tumors, includ

76 conservative strategy consisting of medical therapy alone and angiography reserved for those in whom

77 Notwithstanding, the use of systemic therapy alone can result in a castrate-resistant state;

78 vival than placebo plus androgen-deprivation therapy among men with nonmetastatic, castration-resista

79 likely to receive guideline-directed medical therapies and presented an increased risk for heart fail

80 ICU, however, there is limited data to guide therapies and targets.

81 ne expression facilitates efficient targeted therapies and treatment strategies.

82 low CrAg titers were treated with antifungal therapy and 22 (81%) responded well clinically.

83 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed.

84 t study criteria: 313 (78%) without adjuvant therapy and 90 who received adjuvant chemotherapy with o

85 a stepwise approach of pelvic floor physical therapy and cognitive behavioural therapy as well as med

86 These interactions make combined epigenetic therapy and immunotherapy an attractive approach to circ

87 RIID F6-H2 is an effective postexposure SUDV therapy and provides a potential treatment option for ma

88 ation between the duration of mTOR inhibitor therapy and psoas muscle area on multiple linear mixed-e

89 into account as potential biomarkers in ICI therapy and they may have an impact on the prognostic po

90 r combinations are needed to improve patient therapy and to enhance the effectiveness of intervention

91 d fatty acid synthesis is a valid target for therapy and/or prevention of prostate cancer.

92 ng antidiabetic therapies, anti-inflammatory therapies, and novel immunometabolic agents.

93 o not respond to chemotherapies or radiation therapies, and they are not operable.

94 n opioid use disorder (OUD) treatment during therapy, and 9 remained in OUD treatment after completio

95 state following stress (DNA damage, targeted therapy, and aging).

96 ke value (SUV) metrics to assess response to therapy, and we optimized a preclinical PERCIST paradigm

97 ding HIV infection, 88% under antiretroviral therapy; and 57 women without HIV from the same geograph

98 during heart failure, including antidiabetic therapies, anti-inflammatory therapies, and novel immuno

99 Using a highly novel gene therapy approach in a canine, rapid atrial pacing model

100 Anti-interleukin-6-directed therapies are highly effective in many iMCD patients, bu

101 To reduce rCDI, microbiota-restoring therapies are needed, particularly standardized, easy-to

102 ective in many iMCD patients, but additional therapies are required for refractory cases.

103 ntigen receptor-modified T-cell (CAR-T-cell) therapy are limited.

104 nee osteoarthritis, but the benefits of this therapy are unclear.

105 treatment modalities (e.g., gene and immune therapies) are profoundly changing the oncology landscap

106 In adults starting antiretroviral therapy (ART) during acute infection, 2% of proviruses t

107 tween men and women receiving antiretroviral therapy (ART) is incompletely characterized.

108 We assessed the effect of antiretroviral therapy (ART) on HIV suppression, immune activation, and

109 Patterns of antiretroviral therapy (ART) use and immunologic correlates vary global

110 Antiretroviral therapy (ART) was associated with significantly better T

111 .C.CH505.375H.dCT, and triple antiretroviral therapy (ART) was initiated after 16 weeks.

112 enhanced HIV testing, earlier antiretroviral therapy (ART), and strengthened male circumcision servic

113 in individuals during combination antiviral therapy (ART).

114 reatment confirms the potential of WST-D/NIR therapy as a means of safely stiffening the cornea.

115 r physical therapy and cognitive behavioural therapy as well as medical management is suggested, with

116 nonadherence and nonpersistence to anti-VEGF therapy as well as studies examining strategies to impro

117 d provided preclinical platforms for testing therapies at each tumor grade.

118 lacebo]) and 1 trial of nicotine replacement therapy at 12 months (n = 257; 8.1% vs 8.2%).

119 Patients received adjuvant therapy at physician's discretion.

120 en groups in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative

121 giogenesis is a promising approach to cancer therapy but is limited by the lack of tumor-homing capab

122 y directly kills tumor cells by photodynamic therapy but stimulates the dimeric paclitaxel (PTX) gene

123 d virus (AAV) is a promising vector for gene therapy, but its broad tropism can be detrimental if the

124 Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear.

125 Conclusion: Peptide receptor radionuclide therapy can lead to bowel obstruction in patients with m

126 ed individuals on combination antiretroviral therapy (cART).

127 D completed a course of cognitive-behavioral therapy (CBT).

128 nucleation sites and Mn(2+) for chemodynamic therapy (CDT), resulting in enhanced reactive oxygen spe

129 usehold contacts who received INH preventive therapy compared with 3% (8 of 273) of those who did not

130 rial, a post-debridement systemic antibiotic therapy course for DFO of 3-weeks gave similar (and stat

131 Cardiac resynchronization therapy (CRT) is an established therapy in patients with

132 Given that genetic therapies currently tested in HD are primarily expected

133 At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular re

134 ber pacemakers, 17 cardiac resynchronization therapy defibrillators, and 2 cardiac resynchronization

135 al technique for subretinal gene replacement therapy delivery in pediatric patients exists.

136 ial proportion of patients do not respond to therapy despite being infected with fungi that are susce

137 whether these features respond to anti-VEGF therapies differently.

138 The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inh

139 12 months of follow-up, the probabilities of therapy discontinuation were 49.9% (95% confidence inter

140 Antimicrobial use was tracked using days of therapy (DOT) per 1,000 patient-days, and data were anal

141 tor (hY(1)R) are promising targets in cancer therapy due to their high overexpression on cancer cells

142 277 (51%) of 544 patients commenced therapy early and 267 (49%) commenced therapy late.

143 Alongside efficacy testing of novel therapies, effects on pulmonary pathology and disease pr

144 NP) technologies to further improve the gene therapy efficacy by prolonging the release of nucleic ac

145 r these studies indicate laminin-111 protein therapy either early or late in the disease process coul

146 easingly important asset in developing novel therapies for cancer.

147 time, and the recommendations for switching therapies for convenience and for other reasons are incl

148 heir understanding could offer potential new therapies for CRSwNP (incurable disease).

149 his phenomenon could inform immunomodulatory therapies for HBV cure.

150 function opens new avenues of study and even therapies for hippocampal dysfunction.

151 dividual biological variations and precision therapies for oral health.

152 esponse to the numerous current and emerging therapies for PsD, so that precision medicine can be app

153 Considering the necessity of alternative therapies for this disease of high economic impact and t

154 od and Drug Administration-approved targeted therapy for advanced MCC.

155 ey are unready to quit, and using controller therapy for an extended treatment duration greater than

156 st protocols of adoptive cell transfer (ACT) therapy for cancer, but is limited by short exposure and

157 Monitoring before and during therapy for effectiveness and safety is recommended.

158 mes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra

159 t and Ventricular Remodeling During Entresto Therapy for Heart Failure).

160 ld serve as an effective protein replacement therapy for LAMA2-CMD.

161 FOLFIRINOX has become a standard therapy for patients with advanced PDAC and can be used

162 ctive study, patients who underwent ablation therapy for presumed HCC followed by liver transplantati

163 cuity in both eyes following 3 months of PTX therapy for recurrent liver metastases.

164 Switching therapy for virological failure is relatively rare at th

165 d assessed it in the context of risk-adapted therapy for young patients with NRSTS.

166 either as initial treatment or as step-down therapy from amphotericin B.

167 cterial pneumonia, which requires antibiotic therapy, from viral pneumonia, which does not.

168 he MitraClip plus guideline-directed medical therapy (GDMT) reduced 2-year rates of HF hospitalizatio

169 d 9.3 years (4.9-13.8) in the best available therapy group.

170 usehold contacts who received INH preventive therapy had a lower incidence of tuberculosis disease ev

171 giography reserved for those in whom medical therapy had failed.

172 poietic stem and progenitor cell (HSPC) gene therapy has emerged as an effective treatment modality f

173 many decades, but transcatheter heart valve therapy has revolutionized the field in the past 15 year

174 SMN-restoring therapies have recently emerged; however, preclinical an

175 Anti-T(H) 2 therapies have the potential to effectively reduce airwa

176 ing of bone metastases and their response to therapy have led to adoption of some of these methods in

177 , and especially those receiving combination therapy, have an impaired immune response compared to co

178 se presentation, progression and response to therapy, highlighting heterogeneity in the underlying bi

179 relapse-free survival benefit from targeted therapy (HR [versus placebo] 0.49, 95% CI 0.35-0.68, p<0

180 Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulants.

181 defibrillator and cardiac resynchronization therapy implantation, LVEF improvement (>35%) and recove

182 Immunosuppressive therapy improved patients' HRCT scan scores (P < .0001),

183 Thus, ATR is a major target for cancer therapies in homologous recombination-deficient cancers.

184 rtunities for the future of macrophage-based therapies in oncology are included.

185 ther emphasizes the advantage of combination therapies in prolonging transplant survival.

186 , supporting the potential of these combined therapies in the treatment of advanced atherosclerosis.

187 he cytotoxic effects of HER2 kinase-targeted therapy in a subset of HER2(+) breast cancer cell lines

188 sunate can be used to diversify antimalarial therapy in areas of artemisinin-resistant P. falciparum

189 vity is recommended as a non-pharmacological therapy in both obese and cancer situations.

190 t is vulnerable to inhibition as combination therapy in cancer.

191 icacy of an allogenic MSC-based intramammary therapy in dairy cows with experimentally induced Staphy

192 eks attenuates progression of CKD beyond MRE therapy in mice with type 2 diabetes.

193 n update on known mutations and sulfonylurea therapy in neonatal diabetes mellitus.

194 chronization therapy (CRT) is an established therapy in patients with dilated cardiomyopathy (DCM) an

195 ion of medical management and interventional therapy in preventing symptomatic stroke or death.

196 upport the use of HES for volume replacement therapy in such patients.

197 tralizing antibodies synergize with anti-PD1 therapy in suppressing tumour growth in mouse models of

198 e sutureless AM may be an effective adjuvant therapy in treating sight-threatening infectious corneal

199 olving tumor hemodynamics during bevacizumab therapy in two types of breast cancer xenografts (KPL-4

200 f mouse mammary carcinoma cells to radiation therapy in vitro and in vivo (in immunocompetent syngene

201 ant disease and becomes less prevalent after therapy, in which it is associated with improved outcome

202 s the use of immunomodulator and/or biologic therapies, including thiopurines, methotrexate, cyclospo

203 an ICD experience high rates of appropriate therapies, including those implanted in primary preventi

204 The application of adoptive T cell therapies, including those using chimeric antigen recept

205 ntered the trial to receive genotype-matched therapy-including 14 that re-registered to the trial for

206 Arginine therapy increases mitochondrial activity and reduces oxi

207 to enhance the sophistication of immune cell therapies, increasing potency and safety and broadening

208 This study highlights how therapy-induced adaptation of the multi-cellular ecosyst

209 s, in anticancer immunity, and in anticancer therapies involving DNA damage agents.

210 scontinuation of inappropriate antimicrobial therapy is an important target for stewardship intervent

211 Estrogen therapy is effective in treating patients with advanced

212 ity is high, especially if renal replacement therapy is needed.

213 s.IMPORTANCE While effective, antiretroviral therapy is not a cure for HIV infection.

214 mes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on r

215 Immune checkpoint inhibitor (ICI) therapy is often accompanied by immune-related pathology

216 No effective therapy is yet available to treat triple negative breast

217 HER2-targeted therapies (lapatinib, neratinib, tucatinib and trastuzum

218 menced therapy early and 267 (49%) commenced therapy late.

219 Thus, while periodontal therapy may improve oral health, it may be effective at

220 dividually calibrated biomechanical footwear therapy may improve pain and physical function in people

221 equiring outpatient parenteral antimicrobial therapy must seek treatment in high-risk settings.

222 viral suppression using antiretroviral [ART] therapy; n = 2 with rebound viremia after stopping ART),

223 stricted collateral sensitivities, absent in therapy naive or fully resistant cells, suggesting the p

224 ugs inhibiting MNT could significantly boost therapy of MYC-driven tumors by enhancing intrinsic MYC-

225 ration of and confer resistance to radiation therapy of PDAC.

226 tform, named TCZ-PNPs, for PA-imaging-guided therapy of RA.

227 is study was to test a novel neuromodulation therapy of stimulation of epicardial cardiac nerves pass

228 ents of this composite, and the influence of therapy on eGFR slope.

229 potential harmful effect of any preoperative therapy on the surgical complication rate after pancreat

230 the incidence of acute mucositis (Radiation Therapy Oncology Group and WHO scales) and 36-mo surviva

231 larization (if appropriate) added to medical therapy or an initial conservative strategy consisting o

232 f patients with a history of brain radiation therapy or craniotomy who underwent 1.5-T and 3-T same-p

233 atening pathogen that still lacks a curative therapy or vaccine.

234 propriate local treatments such as radiation therapy, orthopaedic surgery and specialist palliative c

235 nge in response to medical or interventional therapy over 3 months.

236 ibrillators, and 2 cardiac resynchronization therapy pacing systems.

237 Two-year therapy prevented a 1-month-of-life loss, and revealed b

238 1alpha inhibition can enhance antiangiogenic therapy-previously found to be ineffective in patients w

239 Peptide receptor radionuclide therapy (PRRT) with (177)Lu-labeled somatostatin analogs

240 -label fostemsavir plus optimized background therapy (randomized cohort).

241 ntiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced p

242 magnetic resonance imaging only in radiation therapy require methods for predicting the computed tomo

243 ng an indirect stromally targeted avenue for therapy resensitization.See related article by Ford et a

244 -intrinsic NGFR signature predicts anti-PD-1 therapy resistance, and NGFR(hi) tumor fractions are ass

245 nonical Wnt ligand that drives a metastatic, therapy-resistant phenotype, stabilizes the half-life of

246 es of molecular imaging agents for endocrine therapy response.

247 Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than

248 Radiopharmaceutical therapy (RPT) is emerging as a safe and effective target

249 survival, freedom from non-protocol hormone therapy, safety, and patient-reported outcomes.

250 e a way for new synthetic lethal combination therapies.Significance: These findings highlight agents

251 ar risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a

252 A proof-of-concept therapy study with a single administration of (212)Pb-L2

253 cells and restored responsiveness to immune therapy, suggesting an indirect stromally targeted avenu

254 TB patients responding poorly to antibiotic therapy, supporting the role of NETs in a late stage of

255 chanisms could restrict the effectiveness of therapies targeting a single node of the oncogenic signa

256 s for biosynthesis, conferring resistance to therapies targeting anabolic pathways.

257 oven clinically ineffective, and multi-modal therapies targeting mechanisms of immunotherapy resistan

258 Whether therapies targeting these mutations can eradicate premal

259 assess the efficacy of a protease inhibitor therapy targeting neutrophil elastase for the treatment

260 Widespread use of gene therapy technologies is limited in part by the lack of s

261 allowed the development of cell-replacement therapies that comprise dopamine neurons derived from hu

262 would allow the design of network-correcting therapies that treat the core disease mechanism.

263 which 12 were randomized clinical trials of therapy that included 3074 patients, 9 were case series,

264 ow that melanoma cells can adapt to targeted therapies through a mechanosignaling loop involving the

265 visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are needed d

266 d may limit the effectiveness of Ag-specific therapies to distinct disease endotypes.

267 nd assignment of molecular, disease-specific therapies to improve the care of patients with CKD.

268 Additional therapies to reduce CKD incidence, slow CKD progression,

269 to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while

270 , we discuss the current status of potential therapies to target macrophage metabolism during heart f

271 xplosive outbreaks but there are no approved therapies to treat or prevent CHIKV infection.

272 ing patients with recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.83-1.64; N =

273 inhibitors have emerged as a novel clinical therapy to treat homologous recombination-deficient tumo

274 Outcome data from procalcitonin-guided therapy trials have shown similar mortality, but the ess

275 tive, randomized, placebo-controlled hormone therapy trials of conjugated equine estrogens (CEE) amon

276 ements in patient outcomes for 26 first line therapy trials).

277 once every 4 weeks thereafter as maintenance therapy until disease progression or unacceptable toxici

278 our growth and sensitize tumours to targeted therapy via epigenetic reprogramming.

279 t [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inh

280 Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48

281 evention, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients wi

282 Total duration of therapy was determined by treating clinicians and the be

283 MRD at the end of induction therapy was high (>=10(-2) cells) in 61 (66%) of 93 pati

284 >=12, survival after TAVR, SAVR, and medical therapy was similar (1.3 vs. 2.1 vs. 1.6 years, respecti

285 e minimal duration of follow-up after end of therapy was two months.

286 limitations of chemotherapy and photodynamic therapy, we have engineered a robust and smart "all-in-o

287 Known resistance mutations to targeted therapies were numerically more frequent in NCI-MATCH th

288 of neovascular sequelae or need for adjunct therapies were recorded for consecutive visits after mee

289 itivity and an immediate need for antibiotic therapy, when referral to an allergist is not feasible.

290 ed with the combination of belatacept and PI therapy, which significantly reduced both class I and II

291 ar period suggest an unmet need for glaucoma therapies with durable and predictable actions.

292 that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients wit

293 Of 30 patients completing DAA therapy with active illicit opioid use at intake, 14 (46

294 h to mild asthma has long relied on reliever therapy with as-needed short-acting beta-agonists (SABAs

295 Yet, combination therapy with CD40 agonist and Flt3 ligand restores cDC1

296 on may be a useful adjuvant antiangiogenesis therapy with sunitinib.

297 tive at nanomolar concentrations, complement therapy with temozolomide, and synergize strongly with e

298 taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-2206 135 mg/we

299 ngender endogenous patient-specific cellular therapy, without the need for a priori knowledge of tumo

300 o detect disease early and deliver precision therapy would be transformative for the treatment of hum